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Reply: Benefit of genome-wide prenatal cfDNA
testing requires further investigation through a
case–control study
We agree with Bekker et al. that further research is needed
to define the benefits vs harms of genome-wide cell-free
DNA (GW-cfDNA) testing of maternal blood. We believe
that the best approach to answer this question is through a
case–control study in which no action is taken on positive
results other than for trisomies 21, 18 and 13. We strongly
disagree that it is ethically acceptable to ‘test and learn’
through an implementation study such as TRIDENT-21
that is partly funded by the pregnant women themselves
and in which neither the women nor their doctors know
what is the purpose of testing and what is the clinical
significance of most of the positive results other than those
for the major trisomies. Although in The Netherlands a
major effort has been made to optimize pre-test patient
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counseling, the value of such counseling is questionable in
the absence of data on the clinical significance of findings
detected by GW-cfDNA testing.
The situation in Belgium is more worrying. cfDNA
screening is nearly fully funded by the government
and genetic laboratories carry out GW-cfDNA testing
as an ‘opt-out’ test without proper pre-test counseling;
if the pregnant woman does not tick the box stating
that she does not want to be informed about relevant
chromosomal abnormalities other than trisomies 21, 18
and 13, a GW-cfDNA test is conducted2. The Belgian
medical deontological code insists on patients being
correctly informed about any diagnostic or therapeutic
measure they are offered3. However, a recent survey
showed that 20% of women who underwent cfDNA
testing were not aware that this included screening
for trisomy 214.
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